A. Patrikidou

发表

The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation

P. Vlachostergios, D. Daliani, A. Patrikidou, 2009, Journal of cellular and molecular medicine.

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.

J. Blay, C. Antonescu, S. Singer, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises

H. Arkenau, A. Patrikidou, Sabeeh-ur-Rehman Butt, 2019, annals of urologic oncology.

Distant bone metastases from carcinoma of the lip: a report of four cases.

A. Patrikidou, C. Andreadis, K. Antoniades, 2007, International journal of oral and maxillofacial surgery.

Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib

I. Voutsadakis, A. Patrikidou, C. Papandreou, 2010, International Journal of Colorectal Disease.

Nonbacterial Thrombotic (Marantic) Endocarditis in a Patient with Colorectal Cancer

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2010, Oncology Research and Treatment.

PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

B. Escudier, Y. Loriot, R. Flippot, 2022, Drugs.

A novel, de novo germline TP53 mutation in a rare presentation of the Li-Fraumeni syndrome in the maxilla.

P. Abou-Sleiman, J. Delhanty, A. Patrikidou, 2002, Oral oncology.

Pilot study of intraoperative digital imaging with the use of a mammograph for assessment of bone surgical margins in the head and neck region.

K. Paraskevopoulos, A. Patrikidou, D. Gerasimidou, 2013, Clinical radiology.

Proteomics challenging medicine

A. Patrikidou, A. Germenis, 2005 .

Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells

P. Vlachostergios, I. Voutsadakis, A. Patrikidou, 2012, Cancer Cell International.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

J. Bono, Y. Loriot, K. Fizazi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome.

J. Patard, K. Kitikidou, Y. Loriot, 2015, Urologic oncology.

PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

B. Escudier, Y. Loriot, R. Flippot, 2022, Drugs.

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

M. Ducreux, S. Faivre, V. Boige, 2014, Investigational New Drugs.

Baseline Plasma Levels of Interleukin-8 in Stage IV Non-Small-Cell Lung Cancer Patients: Relationship With Nutritional Status and Prognosis

K. Kitikidou, D. Mavroudis, V. Georgoulias, 2012, Nutrition and cancer.

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO).

J. Blay, S. Salas, I. Ray-Coquard, 2018, The oncologist.

Non‐AIDS Kaposi's sarcoma in the head and neck area

A. Patrikidou, R. Valeri, P. Xirou, 2009, Head & neck.

Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis

F. Janot, P. Blanchard, A. Levy, 2017, European Archives of Oto-Rhino-Laryngology.

Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival.

K. Kitikidou, A. Kyrgidis, A. Patrikidou, 2010, European journal of cancer.

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.

B. Escudier, Y. Loriot, K. Fizazi, 2015, European journal of cancer.

A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma.

V. Formica, M. Roselli, H. Arkenau, 2020, Critical reviews in oncology/hematology.

The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls

C. Balleyguier, Y. Loriot, K. Fizazi, 2022, Cancers.

Treading carefully in de-escalation for bone-targeted agents - is less more, after all?

R. Cathomas, A. Patrikidou, 2020, European journal of cancer.

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.

C. Bokemeyer, T. Hermanns, C. Fankhauser, 2020, European urology focus.

Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires.

J. Constantinidis, A. Kyrgidis, A. Patrikidou, 2012, Anticancer research.

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

J. Blay, K. Kitikidou, A. Le Cesne, 2020, BMC Cancer.

Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2011, Cancer Cell International.

p53 and Cyclooxygenase-2 Expression are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-Naïve Prostate Cancer

P. Vlachostergios, D. Daliani, E. Zintzaras, 2012, Pathology & Oncology Research.

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

L. Collette, S. Culine, R. Huddart, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic

J. Patard, B. Escudier, Y. Loriot, 2018, Clinical and translational radiation oncology.

Adnexal Skin Carcinomas of the Face

A. Patrikidou, C. Andreadis, A. Ntomouchtsis, 2009, The Journal of craniofacial surgery.

Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre

K. Kitikidou, A. Kyrgidis, A. Patrikidou, 2019, European Journal of Dermatology.

Prevention of Frey’s Syndrome with the Use of Porcine Dermal Collagen Graft: Retrospective Analysis of 76 “Formal” Parotidectomies for Benign Pathologies

K. Kitikidou, A. Patrikidou, Georgios Koloutsos, 2021, The Annals of otology, rhinology, and laryngology.

The Atkinson Morley's Hospital joint neurosurgical-maxillofacial procedures: cranioplasty case series 1985-2003.

David Uttley, S. Stapleton, A. Patrikidou, 2007, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

Cancer Vaccines

H. Arkenau, A. Patrikidou, V. Dutoit, 2019, Cancer Immunotherapy and Biological Cancer Treatments.

Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?

V. Rodriguez-Bravo, K. Fizazi, A. Patrikidou, 2021, Cancer treatment reviews.

The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation

P. Vlachostergios, D. Daliani, A. Patrikidou, 2009, Journal of cellular and molecular medicine.

Fine-needle aspiration cytology of salivary gland tumours: a 10-year retrospective analysis

Konstantinos Vahtsevanos, Kyriaki Kitikidou, K. Kitikidou, 2012, Oral and Maxillofacial Surgery.

Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma

C. Sternberg, B. Besse, N. Martinez Chanza, 2023, Cancers.

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

H. Moch, T. Bochtler, H. Wasan, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?

K. Fizazi, A. Patrikidou, T. Zilli, 2021, Therapeutic advances in medical oncology.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Y. Loriot, K. Fizazi, A. Patrikidou, 2013 .

Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors

V. Formica, M. Roselli, H. Arkenau, 2020, Targeted Oncology.

Antibiotic prophylaxis for orthognathic surgery: a prospective, randomised clinical trial.

A. Patrikidou, Z. Baqain, M. Harris, 2004, The British journal of oral & maxillofacial surgery.

Comment on: S.S. Prime et al. "A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma" Oral Oncology 2001;37(1), 1-16.

P. Abou-Sleiman, J. Delhanty, A. Patrikidou, 2002, Oral oncology.

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

S. Pignata, U. de Giorgi, S. Rossetti, 2023, Therapeutic advances in medical oncology.

Head and neck Merkel cell carcinoma: a retrospective case series and critical literature review with emphasis on treatment and prognosis.

A. Patrikidou, K. Vahtsevanos, I. Papadiochos, 2018, Oral surgery, oral medicine, oral pathology and oral radiology.

BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series

H. Arkenau, A. Patrikidou, Sabeeh-ur-Rehman Butt, 2021, Cancer Chemotherapy and Pharmacology.

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

S. Pignata, U. de Giorgi, S. Rossetti, 2023, Journal of Translational Medicine.

Magnetic Nanoparticles in Medical Diagnostic Applications: Synthesis, Characterization and Proteins Conjugation

A. Patrikidou, C. Papandreou, V. Zaspalis, 2016 .

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

J. Blay, F. Bertucci, J. Coindre, 2016, European journal of cancer.

716P Optimizing ipilimumab in metastatic renal cell carcinoma: SAKK 07/17 study

R. Cathomas, A. Patrikidou, D. Berthold, 2020 .

Benign Fibrous Histiocytoma of the Buccal Mucosa: Case Report and Literature Review

A. Patrikidou, S. Meditskou, A. Ntomouchtsis, 2010, Case reports in medicine.

Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.

A. Kyrgidis, I. Boukovinas, A. Patrikidou, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A. Russo, V. Formica, M. Roselli, 2021, Annals of palliative medicine.

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

A. Hottinger, S. Momjian, P. Walker, 2019, Neuro-oncology.

Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients

A. Patrikidou, P. Dietrich, V. Dutoit, 2019, Cancers.

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2012, International journal of urology : official journal of the Japanese Urological Association.

Expression of Neutral Endopeptidase, Endothelin-1, and Nuclear Factor Kappa B in Prostate Cancer: Interrelations and Associations with Prostate-Specific Antigen Recurrence after Radical Prostatectomy

P. Vlachostergios, D. Daliani, E. Zintzaras, 2012, Prostate cancer.

CD10 and Endothelin-1 are Inversely Expressed in Early Prostate Cancer and Predict Psa Failure after Radical Prostatectomy

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2011 .

Key messages from the BFR14 trial of the French Sarcoma Group.

A. Le Cesne, A. Patrikidou, 2017, Future oncology.

Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.

J. Blay, F. Bertucci, B. Bui, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Treating soft tissue sarcomas with adjuvant chemotherapy

A. Cesne, A. Patrikidou, A. Cioffi, 2011, Current treatment options in oncology.

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

C. Bokemeyer, T. Hermanns, C. Fankhauser, 2019, Cancer medicine.

Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.

B. Escudier, Y. Loriot, K. Fizazi, 2016, European journal of cancer.

A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma.

R. de Crevoisier, K. Fizazi, A. Patrikidou, 2013, Urologic oncology.

Who dies from prostate cancer?

B. Escudier, Y. Loriot, M. Palma, 2014, Prostate Cancer and Prostatic Disease.

Erratum to: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

P. Vlachostergios, S. Bonanou, G. Simos, 2013, Journal of Molecular Medicine.

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

P. Vlachostergios, S. Bonanou, G. Simos, 2011, Journal of Molecular Medicine.

Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program

K. Kitikidou, A. Patrikidou, R. Valeri, 2016, Pathology & Oncology Research.

European Association of Urology Guidelines on Testicular Cancer: 2023 Update.

D. Berney, C. Fankhauser, J. Boormans, 2023, European urology.

Who dies from prostate cancer in a Western country? A multicenter analysis.

B. Escudier, K. Fizazi, P. Blanchard, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.

E. Dezamis, A. Schernberg, A. Patrikidou, 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival.

J. Blay, J. Coindre, M. Toulmonde, 2011, Journal of Clinical Oncology.

What role does the general practitioner in France play among cancer patients during the initial treatment phase with intravenous chemotherapy? A qualitative study

A. Patrikidou, R. Ourabah, J. Barrière, 2016, The European journal of general practice.

1476P NUTRitional Index for immune-checkpoint inhibitors (ICI) (NUTRICI) for patients (pts) with metastatic gastro-oesophageal junction (GOJ)/gastric cancer (GC)

V. Formica, M. Roselli, A. Patrikidou, 2020 .

Baseline Plasma Levels of Interleukin-8 in Stage IV Non-Small-Cell Lung Cancer Patients: Relationship With Nutritional Status and Prognosis

K. Kitikidou, D. Mavroudis, V. Georgoulias, 2012, Nutrition and cancer.

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.

C. Antonescu, S. Singer, B. Bui, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.

S. Foulon, R. Flippot, A. Patrikidou, 2024, European urology oncology.